LifeMD Inc

LifeMD Inc(LFMD)の株式分析

$2.290

-0.150 (-6.53%)終値時点

Loading chart…
高値
2.490
始値
2.460
出来高加重平均価格
2.33
出来高
597.21K
時価総額
279.29M
安値
2.205
売買代金
1.39M
EV/EBITDA(TTM)
-3.54

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

lifemd.com

AI分析 of LifeMD Inc (LFMD)

買い

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

バリュエーション指標

LifeMD Inc(LFMD)の現在の予想PERは12.85で、5年平均は-15.58です。

予想PER

適正
5年平均 P/E
-15.58
現在のP/E
12.85
割高
43.95
割安
-75.10

予想EV/EBITDA

適正
5年平均 EV/EBITDA
5.86
現在のEV/EBITDA
-3.54
割高
18.37
割安
-6.64

予想PSR

割安
5年平均 P/S
0.93
現在のP/S
0.48
割高
1.37
割安
0.49

Alphio AI による LFMD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%LFMD

$14.58

シナリオ価格

基

基本

基本 · 50%LFMD

$13.42

シナリオ価格

弱

弱気

弱気 · 25%LFMD

$9.37

シナリオ価格

イベントタイムライン

2026-11-05 (ET)

10:00:00

LifeMD Partners with Eli Lilly for Direct GLP-1 Drug Dispensing

2026-09-17 (ET)

12:00:00

H.C. Wainwright Gives LifeMD Buy Rating, Price Target $9

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

ニュース

LFMD のよくある質問 — Alphio AI が回答

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める